loading
Precedente Chiudi:
$4.94
Aprire:
$4.97
Volume 24 ore:
1.32M
Relative Volume:
0.23
Capitalizzazione di mercato:
$1.38B
Reddito:
$8.10M
Utile/perdita netta:
$-92.72M
Rapporto P/E:
-14.13
EPS:
-0.3571
Flusso di cassa netto:
$-82.52M
1 W Prestazione:
-0.27%
1M Prestazione:
+73.50%
6M Prestazione:
+178.36%
1 anno Prestazione:
+157.16%
Intervallo 1D:
Value
$4.94
$5.20
Intervallo di 1 settimana:
Value
$4.43
$5.33
Portata 52W:
Value
$1.05
$5.5082

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Nome
Taysha Gene Therapies Inc
Name
Telefono
(214) 612-0000
Name
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Name
Dipendente
73
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
TSHA's Discussions on Twitter

Confronta TSHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
5.045 1.40B 8.10M -92.72M -82.52M -0.3571
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.50 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.46 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
574.25 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
813.91 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
308.41 34.68B 4.56B -176.77M 225.30M -1.7177

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-11 Iniziato BofA Securities Buy
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-04-09 Iniziato Piper Sandler Overweight
2023-02-01 Downgrade Jefferies Buy → Hold
2023-01-27 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-11-09 Downgrade Goldman Buy → Neutral
2022-03-09 Iniziato Robert W. Baird Outperform
2022-03-01 Iniziato Wells Fargo Overweight
2022-02-18 Iniziato SMBC Nikko Outperform
2021-12-16 Iniziato Guggenheim Buy
2021-07-16 Iniziato Needham Buy
2021-06-24 Iniziato Truist Buy
2021-06-15 Iniziato BTIG Research Buy
2021-06-09 Iniziato Wedbush Outperform
2021-06-08 Iniziato JMP Securities Mkt Outperform
2021-05-19 Iniziato Cantor Fitzgerald Overweight
2021-05-11 Ripresa Jefferies Buy
2021-02-24 Iniziato William Blair Outperform
2021-01-05 Iniziato Oppenheimer Outperform
2020-10-19 Iniziato Chardan Capital Markets Buy
2020-10-19 Iniziato Goldman Buy
2020-10-19 Iniziato Jefferies Buy
2020-10-19 Iniziato Morgan Stanley Overweight
Mostra tutto

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

pulisher
05:23 AM

Why Taysha Gene Therapies Inc. stock is rated strong buyOil Prices & Community Verified Trade Signals - newser.com

05:23 AM
pulisher
01:49 AM

How institutional ownership impacts Taysha Gene Therapies Inc. stock2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com

01:49 AM
pulisher
Oct 22, 2025

Taysha regains full rights to TSHA-102 gene therapy for Rett - Rett Syndrome News

Oct 22, 2025
pulisher
Oct 21, 2025

Chart overlay techniques for tracking Taysha Gene Therapies Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Candlestick signals on Taysha Gene Therapies Inc. stock todayCPI Data & Advanced Technical Analysis Signals - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Why Taysha Gene Therapies Inc. stock is favored by top institutionsQuarterly Market Summary & AI Forecast for Swing Trade Picks - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Tick level data insight on Taysha Gene Therapies Inc. volatilityQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Raymond James Initiates Coverage on TSHA with Strong Buy Rating - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

Taysha soars on FDA breakthrough therapy status for lead asset - MSN

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 00:17:01 - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Why Taysha Gene Therapies Inc. is moving today2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Taysha Gene Therapies Inc. stock continue dividend increasesEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Oct 20, 2025
pulisher
Oct 20, 2025

Using R and stats models for Taysha Gene Therapies Inc. forecastingJuly 2025 Levels & Risk Managed Investment Signals - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

What analysts say about Taysha Gene Therapies Inc stockStock Correlation Metrics & Zero-Cost Stock Research by Professionals - earlytimes.in

Oct 19, 2025
pulisher
Oct 19, 2025

Taysha Gene Therapies Eyes Volatility Amid Key Developments - StocksToTrade

Oct 19, 2025
pulisher
Oct 19, 2025

Taysha Gene Therapies Faces Challenging Market Following Recent Developments - timothysykes.com

Oct 19, 2025
pulisher
Oct 18, 2025

Retail Trends: Can Taysha Gene Therapies Inc. stock double in next 5 yearsJuly 2025 WrapUp & Weekly Stock Breakout Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Taysha Gene Therapies Inc. stock maintain growth story2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Faces Financial Pressure: Concerns Amid Heavy Losses​ - StocksToTrade

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Faces New Challenges Amid Market Volatility - timothysykes.com

Oct 18, 2025
pulisher
Oct 18, 2025

Aug Summary: Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Weekly Earnings: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Retail Activity & Low Drawdown Trading Strategies - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

What catalysts could drive Taysha Gene Therapies Inc. stock higherJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Inc Stock Analysis and ForecastInstitutional Holding Changes & Affordable Portfolio Growth - earlytimes.in

Oct 18, 2025
pulisher
Oct 18, 2025

Can Taysha Gene Therapies Inc. stock hit record highs againJuly 2025 Final Week & Growth Focused Stock Pick Reports - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Sell Signal: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha regains full rights to Rett syndrome gene therapy program By Investing.com - Investing.com Australia

Oct 17, 2025
pulisher
Oct 17, 2025

Why Is Taysha Gene Therapies Stock Falling Friday? - Sahm

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies regains full rights to TSHA-102 - MSN

Oct 17, 2025
pulisher
Oct 17, 2025

Earnings visualization tools for Taysha Gene Therapies Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Bring it back home: Taysha regains gene therapy as option expires - BioWorld MedTech

Oct 17, 2025
pulisher
Oct 17, 2025

I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy - BioPharma Dive

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies regains full rights to TSHA-102 (TSHA:NASDAQ) - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies (TSHA) Rating and Price Target Reaffirmed by Chardan Capital | TSHA Stock News - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034 - GlobeNewswire Inc.

Oct 17, 2025
pulisher
Oct 17, 2025

Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock - Investing.com Canada

Oct 17, 2025
pulisher
Oct 17, 2025

Needham Reiterates Taysha Gene Therapies (TSHA) with "Buy" Ratin - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: 87% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews

Oct 17, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies price target raised to $9 from $8 at BofA - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha (TSHA) Reclaims Full Rights to Key Rett Syndrome Program - GuruFocus

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies Regains Full Rights to TSHA-102 Program - TradingView

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 - GlobeNewswire

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Regains Full Rights to TSHA-102; 100% Part A Response | TSHA Stock News - Stock Titan

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies Hits New 52-Week High at $5.51 - Markets Mojo

Oct 16, 2025
pulisher
Oct 16, 2025

TSHA 8-K: Company announces full rights to TSHA-102 for Rett - Stock Titan

Oct 16, 2025

Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Taysha Gene Therapies Inc Azioni (TSHA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Nagendran Sukumar
President and Head of R&D
Sep 10 '25
Option Exercise
0.70
41,150
28,760
1,206,439
Nagendran Sukumar
President and Head of R&D
Sep 10 '25
Sale
3.23
200,000
646,000
1,006,439
$36.84
price up icon 0.04%
$88.36
price up icon 0.34%
$29.93
price down icon 0.01%
$104.61
price down icon 1.41%
$157.89
price down icon 1.63%
biotechnology ONC
$308.80
price down icon 1.58%
Capitalizzazione:     |  Volume (24 ore):